New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 7, 2014
17:09 EDTFLXNFlexion reports Q2 EPS (38c), consensus (52c)
News For FLXN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 23, 2015
16:11 EDTFLXNFlexion provides outlook on 2015
Michael Clayman, M.D., President and CEO of Flexion, stated, "For Flexion Therapeutics, 2014 was a transformational year. We completed two public stock offerings that place the company in a strong position to execute on its business plan. To that end, the Flexion team has advanced FX006 into two pivotal clinical trials that we expect will form the basis for a regulatory submission for a product that has the potential to make a meaningful and durable difference for the many patients suffering from OA knee pain. In addition, we strengthened our board of directors and management team." Dr. Clayman continued, "We expect 2015 to be another important year for the company as the readout from our first pivotal trial will happen later this year along with completion of enrollment in our Phase 3 trial. With positive data from both trials we look forward to the prospect of filing a New Drug Application thereafter." In 2015, the company expects to announce the results of pivotal Phase 2b trial in the fourth quarter and complete final, pivotal Phase 3 clinical trial enrollment for FX006.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use